ReviewPharmaceutical research2011
Antiviral RNAi: translating science towards therapeutic success.
Review in Pharmaceutical research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Therapeutic Approaches of Viral Gene Silencing by Small Interfering RNA: Strategies to Prevent the Emergence of Antiviral Resistant Escape Mutants.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Antiviral efficacy of short-hairpin RNAs and artificial microRNAs targeting foot-and-mouth disease virus.PeerJ · 2021Article
- Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?Frontiers in microbiology · 2020Review
- Slicing and dicing viruses: antiviral RNA interference in mammals.The EMBO journal · 2019Review
- A review on current status of antiviral siRNA.Reviews in medical virology · 2018Review
- Combination siRNA therapy against feline coronavirus can delay the emergence of antiviral resistance in vitro.Veterinary microbiology · 2015Article
- Formulated minimal-length synthetic small hairpin RNAs are potent inhibitors of hepatitis C virus in mice with humanized livers.Gastroenterology · 2014Article
- VIRsiRNApred: a web server for predicting inhibition efficacy of siRNAs targeting human viruses.Journal of translational medicine · 2013Article
- Regulation of microRNA biogenesis and turnover by animals and their viruses.Cellular and molecular life sciences : CMLS · 2013Review
- Depletion of polycistronic transcripts using short interfering RNAs: cDNA synthesis method affects levels of non-targeted genes determined by quantitative PCR.Virology journal · 2013Article
- RNA interference targets arbovirus replication in Culicoides cells.Journal of virology · 2013Article
- Antiviral effects of small interfering RNA simultaneously inducing RNA interference and type 1 interferon in coxsackievirus myocarditis.Antimicrobial agents and chemotherapy · 2012Article
- VIRsiRNAdb: a curated database of experimentally validated viral siRNA/shRNA.Nucleic acids research · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Viruses continuously evolve to contend with an ever-changing environment that involves transmission between hosts and sometimes species, immune responses, and in some cases therapeutic interventions. Given the high mutation rate of viruses relative to the timescales of host evolution and drug development, novel drug classes that are readily screened and translated to the clinic are needed. RNA interference (RNAi)-a natural mechanism for specific degradation of target RNAs that is conserved from plants to invertebrates and vertebrates-can potentially be harnessed to yield therapies with extensive specificity, ease of design, and broad application. In this review, we discuss basic mechanisms of action and therapeutic applications of RNAi, including design considerations and areas for future development in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.